Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
MONDAY, JUNE 29, 2026
08:00 - 08:50
REGISTRATION AND MORNING REFRESHMENTS
08:50 - 09:00
OPENING ADDRESS
09:00 - 09:30
RESERVED PRESENTATION
09:30 - 09:55
IMPLEMENTATION OF AI IN GxP AREAS OF PHARMA
Loganathan Kumarasamy
Zifo

Loganathan Kumarasamy

Zifo

  • Defining AI implementation in GMP and GCP, from model intent to controlled use in practice
  • Detailing key steps and critical success factors, including EU Annex 22 expectations
  • Readying audit evidence with validation, documentation, and field-tested use case lessons
09:55 - 10:00
Q&A SESSION ON AI IMPLEMENTATION FOR GxP IN PHARMA
10:00 - 10:30
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues – don't forget your business cards!
10:30 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON PHARMA OMICS AND AI
11:30 - 11:55
FULLY-CONNECTED CONTINUOUS MANUFACTURING: UNLOCKING EFFICIENCY AND QUALITY THROUGH AI/ML
Kumar Bala
Enzene Biosciences Ltd.

Kumar Bala

Enzene Biosciences Ltd.

  • Optimizing real-time quality with PAT sensors and analytics to catch deviations early
  • Monitoring connected unit operations continuously, adjusting parameters to protect yield and CQAs
  • Predicting downtime with AI-driven maintenance signals to reduce failures and keep flow steady
  • Streamlining scale-up choices using ML to identify bottlenecks, improve throughput, and compliance
11:55 - 12:00
Q&A SESSION ON AI/ML FOR CONTINUOUS MANUFACTURING
12:00 - 12:25
MAKING MULTI-OMICS ACTIONABLE AT SCALE: THE MMRF MULTIPLE MYELOMA DATA COMMONS, CLINICAL–GENOMIC VISUALIZATION, AND AI/ML-ENABLING DATA FOUNDATIONS
Alex Gout
Multiple Myeloma Research Foundation

Alex Gout

Multiple Myeloma Research Foundation

  • Linking CoMMpass multi-omics to longitudinal outcomes across patients for scalable integration
  • Supporting biomarker discovery and hypothesis generation with translational insight from CoMMpass
  • Enabling cohort exploration via clinical–genomic dashboards for stratification and outcome signals
  • Scaling AI/ML-ready omics with harmonization, QC, metadata governance, and cloud reproducibility
12:25 - 12:30
Q&A SESSION ON MAKING MULTI-OMICS ACTIONABLE AT SCALE
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE PHARMA OMICS & AI EXHIBITION
13:30 - 14:00
PANEL DISCUSSION ON PHARMA OMICS AND AI
14:00 - 14:30
RESERVED PRESENTATION
14:30 - 14:55
HUMAN-RELEVANT MULTIMODAL ONCOLOGY DATA FOR AI/ML TARGET DISCOVERY & TRANSLATIONAL RESEARCH
Alexandre Moreau
Champions Oncology

Alexandre Moreau

Champions Oncology

  • Embedding pre-treated tumour multi-omics into AI discovery and foundation model training
  • Characterising cell-surface and whole-cell proteomics to advance target and biomarker discovery
  • Generating predictive cancer dependency maps using PerturbSeq and patient-derived organoids
14:55 - 15:00
Q&A SESSION ON MULTIMODAL ONCOLOGY DATA FOR TARGET DISCOVERY
15:00 - 15:20
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:20 - 15:50
PANEL DISCUSSION ON PHARMA OMICS AND AI
15:50 - 16:15
AI-ORCHESTRATED LAB-IN-THE-LOOP: MULTI-OBJECTIVE PEPTIDE OPTIMIZATION FOR ORAL BIOAVAILABILITY
Alan Nafiev
RECEPTOR.AI

Alan Nafiev

RECEPTOR.AI

  • Forecasting passive membrane permeability with a hybrid AI and physics-based in silico PAMPA model
  • Transferring membrane permeability to GI permeability through uncertainty-aware delta learning tiers
  • Orchestrating adaptive campaigns with QuorumMap to balance affinity, stability, and permeability
16:15 - 16:20
Q&A SESSION ON PEPTIDE OPTIMIZATION FOR ORAL BIOAVAILABILITY
16:20 - 16:50
RESERVED PRESENTATION
16:50 - 17:15
WHEN DATA RUNS WILD: DATA INTEGRITY AS A CONTROL TOOL IN AI-DRIVEN GXP SYSTEMS
Galit Lisaey
Gal IT Data Integrity Consulting

Galit Lisaey

Gal IT Data Integrity Consulting

  • Governing wild multi-omics inputs so high-dimensional models meet GxP integrity expectations
  • Securing data with cybersecurity and privacy controls that protect GxP purpose and compliance
  • Calibrating intended use, drift risk, and continuous monitoring to stay audit-ready by design
17:15 - 17:20
Q&A SESSION ON DATA INTEGRITY CONTROLS FOR AI IN GXP
17:20 - 18:20
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, JUNE 30, 2026
08:00 - 08:30
MORNING REFRESHMENTS
08:30 - 08:40
OPENING ADDRESS
08:40 - 09:10
PANEL DISCUSSION ON PHARMA OMICS AND AI
09:10 - 09:35
FROM R&D TO CLINICAL TRIALS IN ONE LANDSCAPE – HOW AI HAS CLOSED THE GAP
Heather Bowling
Epistemic AI

Heather Bowling

Epistemic AI

  • Exploring how AI expedites multi-omics analysis for biomarker and target discovery
  • Reviewing how AI has changed clinical trial trend analysis, drawing on an NRDD paper
  • Assessing how AI reshapes the competitive landscape and accelerates new drugs via a case study
09:35 - 09:40
Q&A SESSION ON AI CONNECTING R&D AND CLINICAL TRIALS
09:40 - 10:05
BRIDGING MULTI-OMICS AND FUNCTIONAL PRECISION MEDICINE WITH AI — OLD AND NEW: A SUPPORT VECTOR MACHINE FRAMEWORK FOR PREDICTING DRUG RESPONSE FROM PATIENT MOLECULAR PROFILES
Alan Hauser
Health Discovery Corporation

Alan Hauser

Health Discovery Corporation

  • Closing the gap between ex vivo functional assays and scalable multi-omics for drug choice guidance
  • Selecting compact molecular proxies using SVM-RFE to capture functional drug response signals
  • Predicting Venetoclax sensitivity in BeatAML2 with transcriptomics paired to ex vivo sensitivity data
10:05 - 10:10
Q&A SESSION ON PREDICTING DRUG RESPONSE WITH SVM-RFE AND MULTI-OMICS
10:10 - 10:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
10:30 - 11:00
PANEL DISCUSSION ON PHARMA OMICS AND AI
11:00 - 11:25
MOVING BEYOND RECIST: A CASE STUDY OF THE PANDA PLATFORM FOR MULTIMODAL PATIENT-LEVEL DATA INTEGRATION AND CLINICAL TRIAL RESPONSE PREDICTION
Bryan Allinson
Vanquish AI

Bryan Allinson

Vanquish AI

  • Augmenting RECIST 1.1 with EUS, radiomics, and labs to detect response ahead of shrinkage
  • Fusing multimodal streams in PANDA to synchronise data and generate unified response metrics
  • Scaling orchestration across global sites to manage thousands of participants with consistent signals
  • Differentiating pseudo-progression from true progression to improve immunotherapy trial decisions
11:25 - 11:30
Q&A SESSION ON PANDA PLATFORM FOR RECIST-PLUS RESPONSE METRICS
11:30 - 11:55
PRECISION DATA, IMPRECISE DECISIONS: WHY AI IN PHARMA STRUGGLES TO DELIVER—AND WHAT TO DO ABOUT IT
Beth Bauer
PosiROI, LLC

Beth Bauer

PosiROI, LLC

  • Pinpointing where AI and multi-omics initiatives break down amid data, decision, and incentive gaps
  • Framing a practical model to integrate AI, patient-level data, and human insight for adoption
  • Capitalizing on case-based strategies to build trust, improve decision velocity, and scale outcomes
11:55 - 12:00
Q&A SESSION ON WHY AI IN PHARMA STRUGGLES TO DELIVER
12:00 - 12:25
BUILD IT ONCE, MAKE IT HOLD: DESIGNING AI GOVERNANCE THAT SURVIVES REGULATORY CHANGE
Noel Zamot
AnalytAIX

Noel Zamot

AnalytAIX

  • Fortifying governance for AI around real operations, not one rule at a time today
  • Harmonizing controls to cut duplication, speed decisions, and reduce operational drag
Vishal Bhalla
AnalytAIX

Vishal Bhalla

AnalytAIX

  • Balancing what to standardize enterprise-wide versus localize by jurisdiction and use case
  • Anchoring governance in NIST AI RMF, GDPR, EU AI Act, and ISO/IEC 42001 for change
12:25 - 12:30
Q&A SESSION ON AI GOVERNANCE THAT SURVIVES REGULATORY CHANGE
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE PHARMA OMICS & AI EXHIBITION
13:30 - 13:55
SCALING AI-DRIVEN PROTEIN STRUCTURE PREDICTION FOR DRUG DISCOVERY WITH AWS HEALTHOMICS
Jacob Czech
BioTeam

Jacob Czech

BioTeam

  • Executing compute-heavy protein structure prediction workflows through AWS HealthOmics pipelines
  • Encapsulating model dependencies in containers to keep runs reproducible across large batch jobs
John Jacquay
BioTeam

John Jacquay

BioTeam

  • Parallelizing compute and storage to accelerate structure predictions for drug discovery programs
  • Benchmarking SimpleFold on AWS HealthOmics to confirm performance and operational stability
13:55 - 14:00
Q&A SESSION ON SCALING AI-DRIVEN PROTEIN STRUCTURE PREDICTION
14:00 - 14:25
THE LAST HUMAN ADVANTAGE: WHAT AI CAN'T AUTOMATE—AND WHY THAT'S YOUR ONLY LEVERAGE
M. Sean Agnew
IuvoCare

M. Sean Agnew

IuvoCare

  • Contextualizing chest X-ray misses to show why narrative and backstory still save lives
  • Cultivating contextual courage, translational empathy, and ethical navigation to override bias
  • Reframing hiring and training for judgment, embedding AI copilots, and measuring human impact
14:25 - 14:30
Q&A SESSION ON THE LAST HUMAN ADVANTAGE IN HEALTHCARE
14:30 - 15:00
RESERVED PRESENTATION
15:00 - 15:15
FEEDBACK AND RAFFLE DRAW
15:15 - 15:30
CLOSING REMARKS

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.